Among other receptor tyrosine kinases, toceranib and masitinib both target the tyrosine kinase KIT [69,70,71], which has been frequently described as a prognostic marker and therapy target, especially in canine mast cell tumor [72]. The gene discussed is NTRK1; the disease is mast cell neoplasm.